Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="CORNELY, OA" or (type exact bookEditor and editor="CORNELY, OA")

Add to list
- Journal Article
- A1
- open access
Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine : an EPICOVIDEHA report

J Salmanton-García, F Marchesi, A Glenthøj, YM Bilgin, Jens Van Praet (UGent) , J Dávila-Valls, S Martín-Pérez, J Labrador, J van Doesum, I Falces-Romero, et al.

(2022) HEMASPHERE. 6(11).
Add to list
Diagnosis and management of Aspergillus diseases : executive summary of the 2017 ESCMID-ECMM-ERS guideline

AJ Ullmann, JM Aguado, S Arikan-Akdagli, DW Denning, AH Groll, K Lagrou, C Lass-Flörl, RE Lewis, P Munoz, PE Verweij, et al.

(2018) CLINICAL MICROBIOLOGY AND INFECTION. 24(suppl. 1). p.e1-e38
Add to list
- Conference Paper
- C3
A review of the safety of micafungin compared with liposomal amphotericin B in a large, phase III trial in patients with invasive candidiasis and candidaemia

AJ ULLMANN, Jan De Waele, R BETTS, C ROTSTEIN, M NUCCI and OA CORNELY

(2007) INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 29.
Add to list
- Conference Paper
- C3
An analysis of the efficacy of micafungin in Candida infections caused by non-albicans Candida species in phase III trials

OA CORNELY, Jan De Waele, R BETTS, C ROTSTEIN, M NUCCI, L KOVANDA, C WU and AJ ULLMANN

(2007) INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 29.
Add to list
- Conference Paper
- C3
Efficacy of micafungin in patients with deep, invasive Candida infections

AJ ULLMANN, Jan De Waele, R BETTS, C ROTSTEIN, M NUCCI, L KOVANDA, C WU, D BUELL, H DIEKMANN, S KOBLINGER, et al.

(2007) INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 29.

Academic Bibliography

Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine : an EPICOVIDEHA report

Diagnosis and management of Aspergillus diseases : executive summary of the 2017 ESCMID-ECMM-ERS guideline

A review of the safety of micafungin compared with liposomal amphotericin B in a large, phase III trial in patients with invasive candidiasis and candidaemia

An analysis of the efficacy of micafungin in Candida infections caused by non-albicans Candida species in phase III trials

Efficacy of micafungin in patients with deep, invasive Candida infections

Contents

Support

Contact